These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 8400608

  • 1. Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.
    Reginster JY, Gaspar S, Deroisy R, Zegels B, Franchimont P.
    Osteoporos Int; 1993 Sep; 3(5):261-4. PubMed ID: 8400608
    [Abstract] [Full Text] [Related]

  • 2. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P.
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [Abstract] [Full Text] [Related]

  • 3. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 4. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
    Reginster JY, Denis D, Deroisy R, Lecart MP, De Longueville M, Zegels B, Sarlet N, Noirfalisse P, Franchimont P.
    J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
    [Abstract] [Full Text] [Related]

  • 5. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis.
    Muff R, Dambacher MA, Fischer JA.
    Osteoporos Int; 1991 Feb; 1(2):72-5. PubMed ID: 1790395
    [Abstract] [Full Text] [Related]

  • 6. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
    Overgaard K.
    Calcif Tissue Int; 1994 Aug; 55(2):82-6. PubMed ID: 7953984
    [Abstract] [Full Text] [Related]

  • 7. Salmon calcitonin plus intravaginal estriol: an effective treatment for the menopause.
    Melis GB, Cagnacci A, Bruni V, Falsetti L, Jasonni VM, Nappi C, Polatti F, Volpe A.
    Maturitas; 1996 May; 24(1-2):83-90. PubMed ID: 8794438
    [Abstract] [Full Text] [Related]

  • 8. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
    Thamsborg G, Jensen JE, Kollerup G, Hauge EM, Melsen F, Sorensen OH.
    Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
    [Abstract] [Full Text] [Related]

  • 9. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment.
    Kraenzlin ME, Seibel MJ, Trechsel U, Boerlin V, Azria M, Kraenzlin CA, Haas HG.
    Calcif Tissue Int; 1996 Apr; 58(4):216-20. PubMed ID: 8661950
    [Abstract] [Full Text] [Related]

  • 10. Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women.
    Fioretti P, Gambacciani M, Taponeco F, Melis GB, Capelli N, Spinetti A.
    Maturitas; 1992 Dec; 15(3):225-32. PubMed ID: 1465036
    [Abstract] [Full Text] [Related]

  • 11. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
    Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC.
    Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density.
    Perrone G, Galoppi P, Valente M, Capri O, D'Ubaldo C, Anelli G, Zichella L.
    Gynecol Obstet Invest; 1992 Jul; 33(3):168-71. PubMed ID: 1612530
    [Abstract] [Full Text] [Related]

  • 14. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

  • 15. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
    Plosker GL, McTavish D.
    Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
    [Abstract] [Full Text] [Related]

  • 16. Calcitonin load test to assess the efficacy of salmon calcitonin.
    Stepan JJ, Zikán V.
    Clin Chim Acta; 2003 Oct; 336(1-2):49-55. PubMed ID: 14500034
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of different doses of nasal salmon calcitonin on bone mass.
    Thamsborg G, Storm TL, Sykulski R, Brinch E, Nielsen HK, Sørensen OH.
    Calcif Tissue Int; 1991 May; 48(5):302-7. PubMed ID: 2054714
    [Abstract] [Full Text] [Related]

  • 20. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis.
    Tekeoğlu I, Adak B, Budancamanak M, Demirel A, Ediz L.
    Rheumatol Int; 2005 Dec; 26(2):157-61. PubMed ID: 15660234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.